A Phase III Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Examine the Efficacy and Safety of Iclepertin Once Daily Over 26 Week Treatment Period in Patients With Schizophrenia (CONNEX-2)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 09 Sep 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Iclepertin (Primary)
Indications Schizophrenia
Focus Registrational; Therapeutic Use
Acronyms CONNEX-2
Sponsors Boehringer Ingelheim

Most Recent Events

05 Sep 2024 Planned primary completion date changed from 21 Oct 2024 to 19 Oct 2024.
25 Jun 2024 Planned End Date changed from 13 Nov 2024 to 18 Nov 2024.
29 Apr 2024 Planned End Date changed from 25 Nov 2024 to 13 Nov 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight